Company Encyclopedia
View More
name
Acrivon Therapeutics
ACRV.US
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program.
1.930 T
ACRV.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments

    Acrivon Therapeutics, Inc. received a Buy rating from H.C. Wainwright's analyst Emily Bodnar, with a $19.00 price target, due to promising developments in its ACR-368 Phase 2b trial. The trial's new cohort, which doesn't require a pre-treatment biopsy, is expected to improve enrollment and response rates. Oppenheimer also reiterated a Buy rating with an $8.00 target. These factors contribute to the optimistic outlook for Acrivon.

    Tip Ranks·
    US
    ACRV
    -1.66%
    Tip Ranks·
    US
    ACRV
    -1.66%

    Acrivon Therapeutics Showcases Advances in Precision Proteomics and Next-Generation Medicine in New Corporate Presentation

    Acrivon Therapeutics Inc. has released a corporate presentation detailing advancements in next-generation precision medicine. The presentation highlights the Acrivon Predictive Precision Proteomics (AP3) platform, research and development activities, and key leadership team members. The full presentation is available online. Disclaimer: This AI-generated content is for informational purposes only and not financial, investment, or legal advice. Original content published by Acrivon Therapeutics Inc. on November 21, 2025.

    Reuters·
    US
    ACRV
    -1.66%
    Reuters·
    US
    ACRV
    -1.66%

    Acrivon Therapeutics (NASDAQ:ACRV) Posts Quarterly Earnings Results

    Acrivon Therapeutics reported a quarterly EPS of ($0.47), surpassing analysts' expectations of ($0.57). Despite this, the stock fell 9.2% to $2.07. The company has a market cap of $65.12 million and a consensus rating of 'Moderate Buy' with a target price of $15.00. Institutional investors own 71.62% of the stock. Acrivon is a clinical-stage biopharmaceutical firm focusing on oncology medicines using its proteomics-based platform.

    Market Beat·
    US
    ACRV
    -1.66%
    Market Beat·
    US
    ACRV
    -1.66%

    Acrivon Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ACRV
    -1.66%
    LB filings·
    US
    ACRV
    -1.66%

    Acrivon Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ACRV
    -1.66%
    LB filings·
    US
    ACRV
    -1.66%
    © 2025 Longbridge｜Disclaimer